USE OF DEFENSIN ALPHA 1 AND/OR DEFENSIN ALPHA 4, AS A MARKER FOR PREDICTING TREATMENT RESPONSE AND/OR A RELAPSE IN A PATIENT SUFFERING FROM CHRONIC MYELOID LEUKAEMIA

摘要

The present invention pertains to the use of defensin a1 and/or defensin a4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib.